- Home
- DRCT vs INKT Comparison
DRCT vs INKT Comparison
Compare DRCT & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRCT
- INKT
- Stock Information
- Founded
- DRCT 2018
- INKT 2017
- Country
- DRCT United States
- INKT United States
- Employees
- DRCT N/A
- INKT N/A
- Industry
- DRCT Computer Software: Programming Data Processing
- INKT Medicinal Chemicals and Botanical Products
- Sector
- DRCT Technology
- INKT Health Care
- Exchange
- DRCT Nasdaq
- INKT Nasdaq
- Market Cap
- DRCT 38.7M
- INKT 33.6M
- IPO Year
- DRCT 2022
- INKT 2021
- Fundamental
- Price
- DRCT $0.77
- INKT $8.57
- Analyst Decision
- DRCT Strong Buy
- INKT Strong Buy
- Analyst Count
- DRCT 3
- INKT 2
- Target Price
- DRCT $21.00
- INKT $37.50
- AVG Volume (30 Days)
- DRCT 107.0K
- INKT 10.2K
- Earning Date
- DRCT 04-01-2025
- INKT 03-18-2025
- Dividend Yield
- DRCT N/A
- INKT N/A
- EPS Growth
- DRCT N/A
- INKT N/A
- EPS
- DRCT N/A
- INKT N/A
- Revenue
- DRCT $94,216,000.00
- INKT N/A
- Revenue This Year
- DRCT N/A
- INKT N/A
- Revenue Next Year
- DRCT $37.23
- INKT N/A
- P/E Ratio
- DRCT N/A
- INKT N/A
- Revenue Growth
- DRCT N/A
- INKT N/A
- 52 Week Low
- DRCT $0.51
- INKT $4.56
- 52 Week High
- DRCT $29.75
- INKT $19.00
- Technical
- Relative Strength Index (RSI)
- DRCT 37.13
- INKT 49.63
- Support Level
- DRCT $0.74
- INKT $7.70
- Resistance Level
- DRCT $0.85
- INKT $9.68
- Average True Range (ATR)
- DRCT 0.09
- INKT 0.91
- MACD
- DRCT 0.01
- INKT 0.06
- Stochastic Oscillator
- DRCT 40.47
- INKT 47.47
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform primarily focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.